Fresenius Kabi, revenue | Number of Estimates | | 6 |
Fresenius Kabi, revenue | Highest | | 8,505.2 |
Fresenius Kabi, revenue | Consensus (Mean) | 8,009.0 | 8,438.8 |
Fresenius Kabi, revenue | Median | | 8,427.4 |
Fresenius Kabi, revenue | Lowest | | 8,365.9 |
Fresenius Kabi, organic revenue growth (in %) | Number of Estimates | | 6 |
Fresenius Kabi, organic revenue growth (in %) | Highest | | 6.2 |
Fresenius Kabi, organic revenue growth (in %) | Consensus (Mean) | 7.0 | 5.4 |
Fresenius Kabi, organic revenue growth (in %) | Median | | 5.2 |
Fresenius Kabi, organic revenue growth (in %) | Lowest | | 5.1 |
thereof Medtech, revenue | Number of Estimates | | 5 |
thereof Medtech, revenue | Highest | | 1,642.5 |
thereof Medtech, revenue | Consensus (Mean) | 1,510.0 | 1,604.6 |
thereof Medtech, revenue | Median | | 1,593.1 |
thereof Medtech, revenue | Lowest | | 1,574.7 |
thereof Nutrition, revenue | Number of Estimates | | 5 |
thereof Nutrition, revenue | Highest | | 2,460.3 |
thereof Nutrition, revenue | Consensus (Mean) | 2,304.0 | 2,422.1 |
thereof Nutrition, revenue | Median | | 2,426.6 |
thereof Nutrition, revenue | Lowest | | 2,373.1 |
thereof Biopharma, revenue | Number of Estimates | | 5 |
thereof Biopharma, revenue | Highest | | 512.6 |
thereof Biopharma, revenue | Consensus (Mean) | 363.0 | 481.6 |
thereof Biopharma, revenue | Median | | 471.9 |
thereof Biopharma, revenue | Lowest | | 445.7 |
Subtotal Growth Vectors, revenue | Number of Estimates | | 5 |
Subtotal Growth Vectors, revenue | Highest | | 4,558.2 |
Subtotal Growth Vectors, revenue | Consensus (Mean) | 4,177.0 | 4,508.3 |
Subtotal Growth Vectors, revenue | Median | | 4,525.6 |
Subtotal Growth Vectors, revenue | Lowest | | 4,438.1 |
Pharma (IV Drugs & Fluids), revenue | Number of Estimates | | 5 |
Pharma (IV Drugs & Fluids), revenue | Highest | | 3,948.4 |
Pharma (IV Drugs & Fluids), revenue | Consensus (Mean) | 3,832.0 | 3,932.4 |
Pharma (IV Drugs & Fluids), revenue | Median | | 3,938.7 |
Pharma (IV Drugs & Fluids), revenue | Lowest | | 3,900.2 |
Fresenius Kabi, EBIT | Number of Estimates | | 6 |
Fresenius Kabi, EBIT | Highest | | 1,274.9 |
Fresenius Kabi, EBIT | Consensus (Mean) | 1,145.0 | 1,260.0 |
Fresenius Kabi, EBIT | Median | | 1,267.0 |
Fresenius Kabi, EBIT | Lowest | | 1,236.1 |
Fresenius Kabi, EBIT margin | Number of Estimates | | 6 |
Fresenius Kabi, EBIT margin | Highest | | 15.0 |
Fresenius Kabi, EBIT margin | Consensus (Mean) | 14.3 | 14.9 |
Fresenius Kabi, EBIT margin | Median | | 15.0 |
Fresenius Kabi, EBIT margin | Lowest | | 14.6 |
thereof Growth Vectors, EBIT | Number of Estimates | | 5 |
thereof Growth Vectors, EBIT | Highest | | 563.6 |
thereof Growth Vectors, EBIT | Consensus (Mean) | 390.0 | 486.4 |
thereof Growth Vectors, EBIT | Median | | 478.4 |
thereof Growth Vectors, EBIT | Lowest | | 434.9 |
thereof Growth Vectors, EBIT margin (in %) | Number of Estimates | | 5 |
thereof Growth Vectors, EBIT margin (in %) | Highest | | 12.5 |
thereof Growth Vectors, EBIT margin (in %) | Consensus (Mean) | 9.3 | 10.8 |
thereof Growth Vectors, EBIT margin (in %) | Median | | 10.5 |
thereof Growth Vectors, EBIT margin (in %) | Lowest | | 9.8 |
thereof Pharma (IV Drugs & Fluids), EBIT | Number of Estimates | | 5 |
thereof Pharma (IV Drugs & Fluids), EBIT | Highest | | 833.3 |
thereof Pharma (IV Drugs & Fluids), EBIT | Consensus (Mean) | 792.0 | 809.2 |
thereof Pharma (IV Drugs & Fluids), EBIT | Median | | 811.8 |
thereof Pharma (IV Drugs & Fluids), EBIT | Lowest | | 784.7 |
thereof Pharma (IV Drugs & Fluids), EBIT margin (in %) | Number of Estimates | | 5 |
thereof Pharma (IV Drugs & Fluids), EBIT margin (in %) | Highest | | 21.2 |
thereof Pharma (IV Drugs & Fluids), EBIT margin (in %) | Consensus (Mean) | 20.7 | 20.6 |
thereof Pharma (IV Drugs & Fluids), EBIT margin (in %) | Median | | 20.7 |
thereof Pharma (IV Drugs & Fluids), EBIT margin (in %) | Lowest | | 19.9 |
thereof Corporate, EBIT | Number of Estimates | | 5 |
thereof Corporate, EBIT | Highest | | 0.0 |
thereof Corporate, EBIT | Consensus (Mean) | -37.0 | -37.3 |
thereof Corporate, EBIT | Median | | -37.0 |
thereof Corporate, EBIT | Lowest | | -84.3 |
Fresenius Helios, revenue | Number of Estimates | | 6 |
Fresenius Helios, revenue | Highest | | 12,645.6 |
Fresenius Helios, revenue | Consensus (Mean) | 12,320.0 | 12,500.6 |
Fresenius Helios, revenue | Median | | 12,495.3 |
Fresenius Helios, revenue | Lowest | | 12,397.0 |
Fresenius Helios, organic revenue growth (in %) | Number of Estimates | | 6 |
Fresenius Helios, organic revenue growth (in %) | Highest | | 4.8 |
Fresenius Helios, organic revenue growth (in %) | Consensus (Mean) | 5.0 | 3.5 |
Fresenius Helios, organic revenue growth (in %) | Median | | 3.9 |
Fresenius Helios, organic revenue growth (in %) | Lowest | | 1.2 |
Helios Germany, revenue | Number of Estimates | | 5 |
Helios Germany, revenue | Highest | | 7,609.1 |
Helios Germany, revenue | Consensus (Mean) | 7,279.0 | 7,548.1 |
Helios Germany, revenue | Median | | 7,552.0 |
Helios Germany, revenue | Lowest | | 7,497.4 |
Helios Spain, revenue | Number of Estimates | | 5 |
Helios Spain, revenue | Highest | | 5,034.5 |
Helios Spain, revenue | Consensus (Mean) | 4,770.0 | 4,943.9 |
Helios Spain, revenue | Median | | 4,937.0 |
Helios Spain, revenue | Lowest | | 4,860.6 |
Fresenius Helios, EBIT | Number of Estimates | | 6 |
Fresenius Helios, EBIT | Highest | | 1,281.0 |
Fresenius Helios, EBIT | Consensus (Mean) | 1,232.0 | 1,258.1 |
Fresenius Helios, EBIT | Median | | 1,261.6 |
Fresenius Helios, EBIT | Lowest | | 1,233.6 |
Fresenius Helios, EBIT margin (in %) | Number of Estimates | | 6 |
Fresenius Helios, EBIT margin (in %) | Highest | | 10.2 |
Fresenius Helios, EBIT margin (in %) | Consensus (Mean) | 10.0 | 10.1 |
Fresenius Helios, EBIT margin (in %) | Median | | 10.0 |
Fresenius Helios, EBIT margin (in %) | Lowest | | 10.0 |
Helios Germany, EBIT | Number of Estimates | | 5 |
Helios Germany, EBIT | Highest | | 677.7 |
Helios Germany, EBIT | Consensus (Mean) | 630.0 | 658.2 |
Helios Germany, EBIT | Median | | 654.8 |
Helios Germany, EBIT | Lowest | | 645.3 |
Helios Spain, EBIT | Number of Estimates | | 5 |
Helios Spain, EBIT | Highest | | 618.0 |
Helios Spain, EBIT | Consensus (Mean) | 580.0 | 598.8 |
Helios Spain, EBIT | Median | | 604.3 |
Helios Spain, EBIT | Lowest | | 583.2 |
Helios Corporate, EBIT | Number of Estimates | | 4 |
Helios Corporate, EBIT | Highest | | -4.0 |
Helios Corporate, EBIT | Consensus (Mean) | -4.0 | -4.4 |
Helios Corporate, EBIT | Median | | -4.3 |
Helios Corporate, EBIT | Lowest | | -5.0 |
Fresenius Vamed, revenue | Number of Estimates | | 6 |
Fresenius Vamed, revenue | Highest | | 2,440.3 |
Fresenius Vamed, revenue | Consensus (Mean) | 2,356.0 | 2,339.2 |
Fresenius Vamed, revenue | Median | | 2,318.7 |
Fresenius Vamed, revenue | Lowest | | 2,312.3 |
Fresenius Vamed, organic revenue growth (in %) | Number of Estimates | | 6 |
Fresenius Vamed, organic revenue growth (in %) | Highest | | 5.1 |
Fresenius Vamed, organic revenue growth (in %) | Consensus (Mean) | 1.0 | 2.6 |
Fresenius Vamed, organic revenue growth (in %) | Median | | 4.3 |
Fresenius Vamed, organic revenue growth (in %) | Lowest | | -1.8 |
Fresenius Vamed, EBIT | Number of Estimates | | 6 |
Fresenius Vamed, EBIT | Highest | | 81.2 |
Fresenius Vamed, EBIT | Consensus (Mean) | -16.0 | 58.3 |
Fresenius Vamed, EBIT | Median | | 56.3 |
Fresenius Vamed, EBIT | Lowest | | 48.4 |
Fresenius Vamed, EBIT margin (in %) | Number of Estimates | | 6 |
Fresenius Vamed, EBIT margin (in %) | Highest | | 3.5 |
Fresenius Vamed, EBIT margin (in %) | Consensus (Mean) | -0.7 | 2.5 |
Fresenius Vamed, EBIT margin (in %) | Median | | 2.4 |
Fresenius Vamed, EBIT margin (in %) | Lowest | | 2.0 |
Corporate/Other, revenue | Number of Estimates | | 6 |
Corporate/Other, revenue | Highest | | -296.6 |
Corporate/Other, revenue | Consensus (Mean) | -386.0 | -379.1 |
Corporate/Other, revenue | Median | | -397.0 |
Corporate/Other, revenue | Lowest | | -405.3 |
Corporate/Other, EBIT | Number of Estimates | | 6 |
Corporate/Other, EBIT | Highest | | -95.0 |
Corporate/Other, EBIT | Consensus (Mean) | -99.0 | -157.7 |
Corporate/Other, EBIT | Median | | -167.5 |
Corporate/Other, EBIT | Lowest | | -185.0 |